The people piece of pharma’s digital transformation remains a problem. That is the top takeaway from a GlobalData survey, ...

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...

Months after filing for bankruptcy, VBI Vaccines is taking the next step in shuttering operations with the voluntarily ...

In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...

The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

After pledging to allow politician and vaccine skeptic Robert Francis Kennedy Jr. | Trump's appointment follows his ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...